Browse Category: Medical Research

Eric Lefkofsky Poised For Doing Bigger Things

Eric Lefkofsky is known for his business ventures. These include InnerWorkings as well as Echo Global Logistics besides Groupon.He has earned over $1.79 billion with his e-commerce startups. But he is not resting on his laurels here. He is poised for doing bigger as well as better things. His latest company is called Tempus. It has a huge goal of assembling a genomic database for cancer. This is a humongous exercise. With this database, the doctors will be able to compare the DNA of their patients so that their therapies can be customized. Hence doctors will be able to help their patients suffering from cancer to live much longer. Besides, this will also help to cure many people.

Eric Lefkofsky is well aware that technology is moving at a very high pace. He also realized that it was not moving at the same speed in the medical arena. This is because even though physicians were collecting a large amount of their patients’ data, they were lacking any means for analyzing it.There are many startups along with non-profits that are looking for the best ways for treating diseases. This would require performing several genetic screening tests besides storing the data. This is why technology has grown in a considerable manner in this sector. Eric Lefkofsky feels that Tempus has an advantage over companies.

He has partnered Tempus with several other prominent hospitals. They would be working together to collect enormous amounts of data. Also, Tempus has a 20,000 sq. ft. lab. This can be used for performing several gene-sequencing tests. It provides software to its physicians so that they can compare the DNA profiles of their patients with that of other cancer patients. This way it becomes easier for them to find those treatments which worked best for patients having similar genetic profiles.In 2015 Eric Lefkofsky stepped down as CEO of Groupon. This is because he wanted to focus his efforts on making Tempus a formidable company. He has hired Kevin White as he has wide experience in this industry. He has been involved in building the Institute for Genomics and Systems Biology for 10 years now.

Mikhail Blagosklonny: The Scientist behind Anti-Aging and Cancer Treatment Research

Aging is a process that most people in the world have accepted and made peace with it, apart from a few scientists who have strong conviction that this rather natural process cab be stopped. Cancer too is one of the biggest enemies of the human race, and has a big menace in the world today. But meeting Doctor Mikhail Blagosklonny and getting to read some of his research, a glimpse of hope will shine through the life of many people. Doctor Mikhail is an oncologist and a scientist who has a deep passion for studying cancer through cell division and trying to understand how aging could be related to cancer.

Doctor Mikhail got his education from the First Pavlov State Medical University of St. Petersburg where he got his master’s degree in internal medicine. He went further to get a Ph.D. in Cardiology as well as Experimental Medicine from the same institution. He has put the skills he learned to good use, especially on his hypothesis that claims that TOR signaling has a significant effect on aging and cancer. He suggests the use of Rapamycin, a drug that will help in controlling TOR signaling.

Mikhail is currently working at the Roswell Park Cancer Institute, which is one of the most reputable research institutes for cancer; he has worked here since 2009. He was appointed to work as a professor at this institute due to his extensive research on cancer. Mikhail had previously worked at the New York Medical College as an associate professor, then moved to work with Ordway Research Institute where he worked as a scientist with his research covering the topics of aging, cancer and targeted therapies for cancer among others broadly. Visit ResearchGate.Net to learn more about Mikhail’s latest work.

Mikhail Blagosklonny is recognized as the chief editor of Cell Cycle and Oncotarget. He has also written over 150 medical articles and journals. Mikhail stands as the chief editor in other publications related to cell division studies, anti-aging and cancer in general. He is a strong advocate of the use of Rapamycin drug in treating cancer due to his strong conviction after research that cell division and aging are related to cancer. View Mikhail’s profile in LinkedIn.